Delivering Critical Insights  
at Every Step of Patient Care

Our testing gives you both flexibility and reliability. Labcorp offers dedicated HIV client services and a national infrastructure of more than 2,000 patient service centers. Connectivity solutions range from easy-to-use web based applications to sophisticated integrations that allow efficient and effective communication.

View all HIV test codes

  • Pre-exposure prophylaxis (PrEP)

    We offer the latest CDC-recommended PrEP baseline and monitoring panels for oral and injectable PrEP, helping you minimize unnecessary out-of-pocket costs so you can focus on what matters most: your patients.

    PrEP Testing Capabilities

  • Testing options for screening and diagnosis

    The Centers for Disease Control (CDC) recommends HIV testing for all individuals between ages 13 and 64 at least once as part of standard health care.

    Annual screening is recommended for those persons with known or reported risk factors. All pregnant persons should be tested for HIV.

    HIV Screening and Diagnosis

  • Testing for patients who are newly diagnosed, treatment naïve or experiencing 1st or 2nd therapy failure

    The Department of Health and Human Services (DHHS) Guidelines recommend genotypic testing at baseline and at first and second treatment failures in patients with suboptimal response or virologic failure.1

    Genotypic Testing Capabilities

  • Treatment-experienced patients with a known or suspected complex drug resistance

    Labcorp provides genotypic and phenotypic testing for treatment experienced patients. Labcorp is the only laboratory offering phenotypic testing and combined genotypic-phenotypic testing to determine ARV susceptibility for complex patient scenarios.

    Drug Resistance Testing

  • Testing to support suppression management

    Genotypic testing interrogating the viral archive along with tropism testing of the DNA compartment provide data to support treatment changes without treatment interruption.

    Suppression Management Capabilities

Pre-exposure prophylaxis (PrEP)

We offer the latest CDC-recommended PrEP baseline and monitoring panels for oral and injectable PrEP, helping you minimize unnecessary out-of-pocket costs so you can focus on what matters most: your patients.

PrEP Testing Capabilities

Testing options for screening and diagnosis

The Centers for Disease Control (CDC) recommends HIV testing for all individuals between ages 13 and 64 at least once as part of standard health care.

Annual screening is recommended for those persons with known or reported risk factors. All pregnant persons should be tested for HIV.

HIV Screening and Diagnosis

Testing for patients who are newly diagnosed, treatment naïve or experiencing 1st or 2nd therapy failure

The Department of Health and Human Services (DHHS) Guidelines recommend genotypic testing at baseline and at first and second treatment failures in patients with suboptimal response or virologic failure.1

Genotypic Testing Capabilities

Treatment-experienced patients with a known or suspected complex drug resistance

Labcorp provides genotypic and phenotypic testing for treatment experienced patients. Labcorp is the only laboratory offering phenotypic testing and combined genotypic-phenotypic testing to determine ARV susceptibility for complex patient scenarios.

Drug Resistance Testing

Testing to support suppression management

Genotypic testing interrogating the viral archive along with tropism testing of the DNA compartment provide data to support treatment changes without treatment interruption.

Suppression Management Capabilities

We are an acknowledged world leader 
in HIV resistance and tropism testing

Unsurpassed Scientific Expertise

  • Labcorp brings an unrivaled level of scientific expertise to HIV diagnostics.
  • Our highly qualified team includes elite scientists and experienced HIV specialists, all committed to advancing patient care via individualized HIV-1 treatments.
  • Labcorp’s experienced medical affairs professionals are available for consultations and educational programs.

History of vision and innovation

  • Labcorp was an early pioneer in polymerase chain reaction (PCR) technology and molecular diagnostics for HIV.
  • Labcorp has had a role in nearly every new HIV drug development since the early 1990s.
  • Labcorp has ongoing collaborations with leading pharmaceutical companies to help bring next-generation therapeutic innovations to market.

Reference